ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)
1Hedi Chaker University Hospital, Sfax, Tunisia; 2Hedi Chaker University Hospital, Endocrinology Department, Sfax, Tunisia; 3Hedi Chaker Univeristy Hospital, Sfax, Tunisia
JOINT422
Background: Metabolic Associated Steatotic Liver Disease (MASLD) is a growing global health concern. The coexistence of MASLD and Type 2 Diabetes Mellitus (T2DM) poses a significant clinical challenge, as both conditions are intertwined through common pathophysiological mechanisms. Understanding the prevalence of MASLD in T2DM patients is crucial for developing effective screening, prevention, and treatment strategies. This study aims to investigate the prevalence of MASLD in T2DM patients.
Methods: This was a retrospective study that included patients followed for T2DM from 2012 to 2024 at the Endocrinology and Diabetology Department of the Hedi Chaker University Hospital in Sfax, Tunisia. The diagnosis of MASLD within T2DM patients was based on the 2024 EASL-EASD-EASO guidelines on the Management of MASLD.
Results: A total of 734 patients with T2DM was recruted and underwent abdominal imaging. 609 patients (83%) had normal imaging results, while 125 patients (17.03%) were diagnosed with hepatic steatosis. Thus, the prevalence of MASLD in our cohort of T2DM patients was found to be 17.03%. The mean age of the diabetic patients with MASLD was 53.7 (±15.2) years, with a female predominance of 62.4%.
Conclusion: Our study provides valuable insights into the burden of this dual diagnosis emphasizing its clinical significance. These findings highlight the critical need for early detection and effective management of MASLD in diabetic patients.